Synthesis and biological evaluation of nitric oxide (NO)-hydrogen sulfide (H2S) releasing derivatives of (S)-3-n-butylphthalide as potential antiplatelet agents.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Chinese Journal of Natural Medicines

• Publication date

  2016-12-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/S1875-5364(17)30021-3PMID 28262123
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Design, synthesis and biological evaluation of hydrogen sulfide releasing derivatives of 3-n-butylphthalide as potential antiplatelet and antithrombotic agents.

  2014cited by this paper
• Synthesis and biological evaluation of nitric oxide releasing derivatives of 6-amino-3-n-butylphthalide as potential antiplatelet agents.

  2013cited by this paper
• Novel hybrids of optically active ring-opened 3-n-butylphthalide derivative and isosorbide as potential anti-ischemic stroke agents.

  2013cited by this paper
• Synthesis and biological activity of NOSH-naproxen (AVT-219) and NOSH-sulindac (AVT-18A) as potent anti-inflammatory agents with chemotherapeutic potential.

  2013cited by this paper
• NOSH-Aspirin: A Novel Nitric Oxide-Hydrogen Sulfide-Releasing Hybrid: A New Class of Anti-inflammatory Pharmaceuticals.

  2012cited by this paper
• Antiplatelet treatment in primary and secondary stroke prevention in women.

  2012cited by this paper
• Stroke genetics.

  2011cited by this paper
• Synthesis and evaluation of nitric oxide-releasing derivatives of 3-n-butylphthalide as anti-platelet agents.

  2011cited by this paper
• New nitric oxide or hydrogen sulfide releasing aspirins.

  2011cited by this paper
• l-3-n-Butylphthalide Improves Cognitive Impairment and Reduces Amyloid-β in a Transgenic Model of Alzheimer's Disease

  2010cited by this paper
• Thrombin-Activatable Fibrinolysis Inhibitor (TAFI) Deficient Mice Are Susceptible to Intracerebral Thrombosis and Ischemic Stroke

  2010cited by this paper
• Thrombin Mediates Severe Neurovascular Injury During Ischemia

  2010cited by this paper
• Novel Insights Into Hydrogen Sulfide–Mediated Cytoprotection

  2010cited by this paper
• Cerebral Blood Flow Regulation by Nitric Oxide: Recent Advances

  2009cited by this paper
• DL-3-n-butylphthalide protects endothelial cells against oxidative/nitrosative stress, mitochondrial damage and subsequent cell death after oxygen glucose deprivation in vitro.

  2009cited by this paper
• Hydrogen sulphide in the hypothalamus causes an ATP-sensitive K+ channel-dependent decrease in blood pressure in freely moving rats.

  2008cited by this paper
• Redox-based regulation of signal transduction: principles, pitfalls, and promises.

  2008cited by this paper
• Triggers, targets and treatments for thrombosis

  2008cited by this paper
• Stroke and Thrombolysis in Developing Countries

  2007cited by this paper
• Hydrogen sulphide and its therapeutic potential

  2007cited by this paper
• Anti-inflammatory and gastrointestinal effects of a novel diclofenac derivative.

  2007cited by this paper
• Nitric oxide and peroxynitrite in health and disease.

  2007cited by this paper
• 2-(1-Hydroxypentyl)-benzoate Increases Cerebral Blood Flow and Reduces Infarct Volume in Rats Model of Transient Focal Cerebral Ischemia

  2006cited by this paper
• Platelet ADP receptor antagonists: ticlopidine and clopidogrel.

  2004cited by this paper
• Effects of 2‐(1‐hydroxypentyl)‐benzoate on platelet aggregation and thrombus formation in rats

  2004cited by this paper
• The novel neuromodulator hydrogen sulfide: an endogenous peroxynitrite ‘scavenger’?

  2004cited by this paper
• The regulatory effect of hydrogen sulfide on hypoxic pulmonary hypertension in rats.

  2003cited by this paper

• Research progress of 3-n-butylphthalide and its derivatives in combating cerebral ischemia.

  2026cites this paper
• Hydrogen sulfide in placental development and pregnancy disorders: mechanisms, therapeutic potential, and translational challenges

  2025cites this paper
• Codelivery of Gaseous Signaling Molecules for Biomedical Applications.

  2024cites this paper
• Research progress of prodrugs for the treatment of cerebral ischemia.

  2024cites this paper
• Advances in nitric oxide regulators for the treatment of ischemic stroke.

  2023cites this paper
• Efficacy and safety of butylphthalide in secondary prevention of stroke: study protocol for a multicenter, real world trial based on Internet

  2022cites this paper
• Research Progress of H2S Donors Conjugate Drugs Based on ADTOH

  2022cites this paper
• Butylphthalide Combined With Conventional Treatment Attenuates MMP-9 Levels and Increases VEGF Levels in Patients With Stroke: A Prospective Cohort Study

  2021cites this paper
• DL-3n-Butylphthalide Improves Blood–Brain Barrier Integrity in Rat After Middle Cerebral Artery Occlusion

  2021cites this paper
• Hydrogen sulfide donors: Therapeutic potential in anti-atherosclerosis.

  2020cites this paper
• Hydrogen sulfide reduces the activity of human endothelial cells

  2020cites this paper
• L-3-n-butylphthalide attenuates inflammation response and brain edema in rat intracerebral hemorrhage model

  2020cites this paper
• L-3-n-butylphthalide protect the neuro by reducing inflammation and brain edema in rat intracerebral hemorrhage model

  2019cites this paper
• Application and prospects of butylphthalide for the treatment of neurologic diseases

  2019cites this paper
• Dl-3-n-butylphthalide Reduces Neurovascular Inflammation and Ischemic Brain Injury in Mice

  2019cites this paper
• L-3-n-butylphthalide attenuates inflammation and brain edema in rat intracerebral hemorrhage model

  2019cites this paper
• The effects of hydrogen sulfide on microvascular circulation in the axial pattern flap ear model in hairless mice.

  2018cites this paper
• Docking based design of diastereoisomeric MTCA as GPIIb/IIIa receptor inhibitor.

  2017cites this paper
• International Union of Basic and Clinical Pharmacology. CII: Pharmacological Modulation of H2S Levels: H2S Donors and H2S Biosynthesis Inhibitors

  2017influential citation